Expedited approval of new drugs is one of the oldest issues in the pharmaceutical industry. Shortening the insurance reimbursement review period for drugs has been discussed almost every year, and in fact, the regulatory deadline is getting shorter and shorter.

This is true for both the evaluation and negotiation stages of the Health Insurance Review and Assessment Service and the National Health Insurance Service. However, it is also true that the deadline is only a deadline set for the pharmaceutical company to apply and the authorities review the application, so it is not proving to be effective in expediting the reimbursement of new drugs.

The responsibility lies on both sides. Firs